Filing Details

Accession Number:
0001645113-20-000124
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-09-03 16:37:10
Reporting Period:
2020-09-01
Accepted Time:
2020-09-03 16:37:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1645113 Novocure Ltd NVCR Surgical & Medical Instruments & Apparatus (3841) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1744884 Pritesh Shah C/O Novocure Inc.,
20 Valley Stream Parkway, Suite 300
Malvern PA 19355
Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Restricted Share Units Acquisiton 2020-09-01 1,968 $0.00 102,986 No 4 A Direct
Ordinary Shares Disposition 2020-09-02 4,200 $85.01 98,786 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Options to Buy Ordinary Shares Acquisiton 2020-09-01 3,779 $0.00 3,779 $84.68
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
3,779 2030-08-31 No 4 A Direct
Footnotes
  1. Represents restricted share units that are scheduled to vest in equal installments on September 1, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates.
  2. On September 2, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 4200 shares in multiple trades at prices ranging from $85.00 to $85.02. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
  3. Options to buy 3,779 ordinary shares will vest and become exercisable in equal installments on each of September 1, 2021, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates.